PPP1R13L
RelA-associated inhibitor
Protein Summary
Regulator that plays a central role in regulation of apoptosis and transcription via its interaction with NF-kappa-B and p53/TP53 proteins. Blocks transcription of HIV-1 virus by inhibiting the action of both NF-kappa-B and SP1. Also inhibits p53/TP53 function, possibly by preventing the association between p53/TP53 and ASPP1 or ASPP2, and therefore suppressing the subsequent activation of apoptosis. IASPP is one of the most evolutionarily conserved inhibitors of p53 (TP53; MIM 191170), whereas ASPP1 (MIM 606455) and ASPP2 (MIM 602143) are activators of p53.[supplied by OMIM, Mar 2008]
- ENST00000360957
- ENSP00000354218
- ENSG00000104881
- ENST00000418234
- ENSP00000403902
- IASPP
- NKIP1
- PPP1R13BL
- RAI
- RAI
- RAI4
- IASPP
- NKIP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.83 | ||
biological process | 0.74 | ||
transcription factor | 0.74 | ||
histone modification site profile | 0.73 | ||
tissue sample | 0.72 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 106.38 (req: < 5)
Gene RIFs: 101 (req: <= 3)
Antibodies: 235 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 106.38 (req: >= 5)
Gene RIFs: 101 (req: > 3)
Antibodies: 235 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 17
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0